


-109-
CLAIMS

What is claimed is:

1. A compound of the formula:




wherein:

X is NH, O or S;


R₁ is selected from halogen, -C=CH₂, -O-C₁-C₆ alkyl, -C=CH-(CH₂)_m-O-C₁-C₆ alkyl, -C=C-(CH₂)_m-O-C₁-C₆ alkyl, -C=C-(CH₂)_m-NH-C₁-C₆ alkyl, -C≡CH, -C≡C-(CH₂)_m-OH, C≡C-(CH₂)_m-NH₂, -COOH, -(CH₂)_m-COOH, -CONH₂, -COO-C₁-C₆ alkyl, -(CH₂)_m-CONH₂, -C(O)(C₁-C₆ alkyl), -C(O)NHSO₂H, -(CH₂)_m-C(O)NHSO₂H, -C(O)NHSO₂-(C₁-C₃ alkyl), -(CH₂)_m-C(O)NHSO₂-(C₁-C₃ alkyl), or C₁-C₆ alkyl, -S-C₁-C₆ alkyl or alkenyl, with the alkyl, -S-alkyl and alkenyl chains in each of these R₁ moieties being optionally substituted by from 1 to 3 OH groups and/or by from 1 to 5 fluorine atoms;

R₂ is -R₃, -O-R₃, -S-R₃ or a moiety selected from the group of NH₂, NHR₃, N(C₁-C₃ alkyl)-R₃, -NH-(CH₂)_n-O-(C₁-C₃ alkyl), -NH-(CH₂)_n-O-C(O)-(C₁-C₃ alkyl) or -N((CH₂)_n-O-(C₁-C₃ alkyl))₂, or a moiety selected from the group of:




R_3 is a moiety selected from:

- 5 a) C_1 - C_8 alkyl, C_1 - C_8 alkenyl, the alkyl and alkenyl groups each being optionally substituted by from 1 to 4 OH or halogen groups;
- 10 b) $-(CH_2)_n-NH_2$, $-(CH_2)_n-NH(C_1-C_3 \text{ alkyl})$, $-(CH_2)_n-N(C_1-C_3 \text{ alkyl})_2$, $-(CH_2)_n-O-(C_1-C_3 \text{ alkyl})$, $-(CH_2)_m-C(O)-O-(C_1-C_3 \text{ alkyl})$, or $(CH_2)_n-N(C_1-C_3 \text{ alkyl})-C(O)-(C_1-C_3 \text{ alkyl})$;
- 15 c) phenyl, $-(CH_2)_m$ -phenyl, $-(CH_2)_m$ -O-phenyl, the phenyl ring of each being optionally substituted by 1 or 2 groups selected from C_1 - C_3 alkoxy, NH_2 , $NH(C_1-C_3 \text{ alkyl})$, $N(C_1-C_3 \text{ alkyl})_2$; or
- d) a moiety selected from the group of:



- 5 R_4 is selected from H or C_1 - C_3 alkyl, optionally substituted by OH;
 R_5 is selected from H or halogen;
 R_6 is selected from H or F;
 R_7 is selected from F, CH_2F , CHF_2 , or $-CF_3$;
n in each instance is independently selected as an integer of from 1 to 6
10 m in each instance is independently selected as an integer of from 1 to 4;
or a pharmaceutically acceptable salt or ester form thereof.

2. A compound of Claim 1 of the formula:



wherein:

- 5 R_1 is selected from I, Br or C_1 - C_3 alkyl;

R_2 is R_3 , $-O-R_3$, $-S-R_3$ or a moiety selected from the group of NH_2 , NHR_3 , $N(C_1-C_3 \text{ alkyl})-R_3$, $-NH-(CH_2)_n-O-(C_1-C_3 \text{ alkyl})$, $-NH-(CH_2)_n-O-C(O)-(C_1-C_3 \text{ alkyl})$ or $-N((CH_2)_n-O-(C_1-C_3 \text{ alkyl}))_2$;

- 10 R_3 is a moiety selected from:


a) C_1 - C_8 alkyl, C_1 - C_8 alkenyl, the alkyl and alkenyl groups each being optionally substituted by from 1 to 4 OH groups;

- 15 b) $-(CH_2)_n-NH_2$, $-(CH_2)_n-NH(C_1-C_3 \text{ alkyl})$, $-(CH_2)_n-N(C_1-C_3 \text{ alkyl})_2$, $-(CH_2)_n-O-(C_1-C_3 \text{ alkyl})$, $-(CH_2)_m-C(O)-O-(C_1-C_3 \text{ alkyl})$,

c) phenyl, $-(CH_2)_m$ -phenyl, $-(CH_2)_m$ -O-phenyl, the phenyl ring of each being optionally substituted by 1 or 2 groups selected from C_1 - C_3 alkoxy, NH_2 , $NH(C_1-C_3 \text{ alkyl})$, $N(C_1-C_3 \text{ alkyl})_2$; or

20

- d) a moiety selected from the group of:



- 5 R_4 is selected from H or C_1 - C_3 alkyl, optionally substituted by OH;
 n is an integer of from 1 to 6
 m is an integer of from 1 to 4;
or a pharmaceutically acceptable salt form thereof.

- 10 3. A compound of Claim 1 selected from the group of:
5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-ylamine;
5-[5-Chloro-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-ylamine;
15 5-[2-(4-Bromo-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-
[1,3,4]oxadiazol-2-ylamine;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-ethyl-amine;

Allyl-{5-[3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-amine;

5 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(2,4-dimethoxy-phenyl)-amine;

N-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-*N*',*N*'-dimethyl-benzene-1,4-diamine;

10 3-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-ylamino}-propane-1,2-diol;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(3-morpholin-4-yl-propyl)-amine
hydrochloride salt;

15 *N*-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-*N*',*N*'-diethyl-propane-1,3-diamine;

or a pharmaceutically acceptable salt form thereof.

4. A compound of Claim 1 selected from the group of:

20 *N*'1'-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-ethane-1,2-diamine as a trifluoro-acetic
acid;

N-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-*N*,*N*',*N*'-trimethyl-propane-1,3-diamine;

25 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(2-piperidin-1-yl-ethyl)-amine;

N'1'-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-butane-1,4-diamine;

N'1'-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-propane-1,3-diamine;

30 *N*-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-*N*',*N*'-dimethyl-propane-1,3-diamine;

N-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-*N*',*N*'-dimethyl-ethane-1,2-diamine;

N-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-*N'*-methyl-ethane-1,2-diamine;
N-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-2,2,*N'*,*N'*-tetramethyl-propane-1,3-diamine;
5 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(3-methoxy-propyl)-amine;
or a pharmaceutically acceptable salt form thereof.

5. A compound of Claim 1 selected from the group of:

10 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(2-morpholin-4-yl-ethyl)-amine;
(2,3-Difluoro-6-{5-[4-(2-methoxy-ethyl)-piperazin-1-yl]-[1,3,4]oxadiazol-
2-yl}-phenyl)-(2-fluoro-4-iodo-phenyl)-amine;
5-5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
15 [1,3,4]oxadiazol-2-ylamino)-2,2-dimethyl-pentan-1-ol;
1-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-pyrrolidin-3-ol;
(1-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-piperidin-4-yl)-methanol;
20 2-(1-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-piperidin-4-yl)-ethanol;
4-({5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-ethyl-amino)-butan-1-ol;
1-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
25 [1,3,4]oxadiazol-2-yl}-piperidin-4-ol
2-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-ylamino)-ethanol;
3-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-ylamino)-propan-1-ol;
30 or a pharmaceutically acceptable salt form thereof.

6. A compound of Claim 1 selected from the group of:

4-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-ylamino}-butan-1-ol;

5-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-ylamino}-pentan-1-ol;

5 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(2-methoxy-ethyl)-amine;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(2-phenoxy-ethyl)-amine;

10 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(2-pyridin-4-yl-ethyl)-amine;

Butyl-{5-[3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-amine;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(5-methyl-furan-2-ylmethyl)-amine;

15 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(2-thiophen-2-yl-ethyl)-amine;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-[2-(3-methoxy-phenyl)-ethyl]-amine;

20 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-[2-(3,4-dimethoxy-phenyl)-ethyl]-amine;

or a pharmaceutically acceptable salt form thereof.

7. A compound of Claim 1 selected from the group of:

25 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-[2-(2,5-dimethoxy-phenyl)-ethyl]-amine;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-
amine;

30 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-methyl-(2-pyridin-4-yl-ethyl)-amine;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-methyl-(2-pyridin-2-yl-ethyl)-amine;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-propyl-amine;
sec-Butyl-{5-[3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-amine;

5 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(2,2-dimethyl-propyl)-amine;
{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-isobutyl-amine;
10 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(1,2,2-trimethyl-propyl)-amine;
{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(2-methyl-butyl)-amine;

or a pharmaceutically acceptable salt form thereof.

15 8. A compound of Claim 1 selected from the group of:

Bicyclo[2.2.1]hept-2-yl-{5-[3,4-difluoro-2-(2-fluoro-4-iodo-
phenylamino)-phenyl]-[1,3,4]oxadiazol-2-yl}-amine;
{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-[2-(1-methyl-1H-pyrrol-2-yl)-ethyl]-amine;
20 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-[2-(1-methyl-1H-imidazol-4-yl)-ethyl]-
amine;
{2,3-Difluoro-6-[5-(2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-
[1,3,4]oxadiazol-2-yl]-phenyl}-(2-fluoro-4-iodo-phenyl)-amine;
25 {5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(2-methoxy-1-methyl-ethyl)-amine;
{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(3-ethoxy-propyl)-amine;
3-5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
30 [1,3,4]oxadiazol-2-ylamino}-dihydro-furan-2-one;
3-5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-ylamino}-propionic acid;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-[2-(2,6-dimethyl-phenoxy)-1-methyl-ethyl]-
amine;

(1-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-pyrrolidin-3-yl)-diethyl-amine;
or a pharmaceutically acceptable salt or ester form thereof.

9. A compound of Claim 1 selected from the group of:

{2,3-Difluoro-6-[5-(4-methyl-[1,4]diazepan-1-yl)-[1,3,4]oxadiazol-2-yl]-
phenyl}-(2-fluoro-4-iodo-phenyl)-amine;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amine;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(4-pyrrolidin-1-yl-butyl)-amine;

N*4*-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-N*1*,N*1*-diethyl-pentane-1,4-diamine;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-(tetrahydro-furan-2-ylmethyl)-amine;

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]oxadiazol-2-yl}-bis-(2-methoxy-ethyl)-amine;

N-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-
[1,3,4]oxadiazol-2-yl}-N'-methyl-ethane-1,2-diamine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-
[1,3,4]oxadiazol-2-yl}-(2-morpholin-4-yl-ethyl)-amine;

2-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-
[1,3,4]oxadiazol-2-ylamino}-ethanol;

Allyl-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-
[1,3,4]oxadiazol-2-yl}-amine;

or a pharmaceutically acceptable salt form thereof.

10. A compound of Claim 1 selected from the group of:

{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-
[1,3,4]thiadiazol-2-yl}-ethyl-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(3-pyrrolidin-1-yl-propyl)-amine;

N¹,N¹-Diethyl-N2-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-ethane-1,2-diamine;

5 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-isopropyl-amine;

[2,3-Difluoro-6-(5-pyrrolidin-1-yl-1,3,4-oxadiazol-2-yl)-phenyl]-(4-ethyl-2-fluoro-phenyl)-amine;

10 N¹-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N>3_-methyl-propane-1,3-diamine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-furan-2-ylmethyl-amine;

(2,2-Dimethoxy-ethyl)-{5-[2-(ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-amine;

15 {2,3-Difluoro-6-[5-(4-phenyl-piperazin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-methoxy-ethyl)-amine;

or a pharmaceutically acceptable salt form thereof.

20

11. A compound of Claim 1 selected from the group of:

6-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-ylamino}-hexanenitrile;

25 (3,3-Diethoxy-propyl)-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-amine;

Diallyl-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(3-methylsulfanyl-propyl)-amine;

30 4-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-ylamino}-isoxazolidin-3-one;

N¹-Ethyl-N¹-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N²,N²-dimethyl-ethane-1,2-diamine;

{2,3-Difluoro-6-[5-(4-methyl-perhydro-1,4-diazepin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;
1-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-piperidine-3-carboxylic acid diethylamide;
5 N-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-O-(tetrahydro-pyran-2-yl)-hydroxylamine;
{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(3-morpholin-4-yl-propyl)-amine;
or a pharmaceutically acceptable salt form thereof.

10

12. A compound of Claim 1 selected from the group of:

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(4H-1,2,4-triazol-3-yl)-amine;
N¹-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N2-methyl-ethane-1,2-diamine;
15 N¹-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N1,N>3,N>3-trimethyl-propane-1,3-diamine;
{2,3-Difluoro-6-[5-(4-pyridin-2-yl-piperazin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;
20 N²-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N1,N1-dimethyl-propane-1,2-diamine;
N¹-(3-Dimethylamino-propyl)-N¹-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N>3,N>3-dimethyl-propane-1,3-diamine;
25 N¹-Cyclohexyl-N>3-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-propane-1,3-diamine;
{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-phenoxy-ethyl)-amine;
{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-morpholin-4-yl-ethyl)-amine;
30 Cyclopropylmethyl-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-propyl-amine;
or a pharmaceutically acceptable salt form thereof.

13. A compound of Claim 1 selected from the group of:

(4-Ethyl-2-fluoro-phenyl)-{6-[5-(4-ethyl-piperazin-1-yl)-1,3,4-oxadiazol-2-yl]-2,3-difluoro-phenyl}-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-methyl-(1-methyl-pyrrolidin-3-yl)-amine;

N¹,N¹-Diethyl-N2-(2-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-ylamino}-ethyl)-ethane-1,2-diamine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-thiophen-2-ylmethyl-amine;

{2,3-Difluoro-6-[5-(4-pyrrolidin-1-yl-piperidin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(tetrahydro-pyran-2-ylmethyl)-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-pyridin-4-yl-ethyl)-amine;

{6-[5-(4-Benzyl-perhydro-1,4-diazepin-1-yl)-1,3,4-oxadiazol-2-yl]-2,3-difluoro-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-pyridin-2-ylmethyl-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(5-methyl-furan-2-ylmethyl)-amine;

or a pharmaceutically acceptable salt form thereof.

14. A compound of Claim 1 selected from the group of:

(2-Ethoxy-benzyl)-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-amine;

{2,3-Difluoro-6-[5-(4-methyl-piperazin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-pyridin-3-ylmethyl-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-thiophen-2-yl-ethyl)-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-pyridin-3-yl-ethyl)-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-pyridin-4-ylmethyl-amine;

5 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-pyridin-2-yl-ethyl)-amine;

N-(2-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-ylamino}-ethyl)-acetamide;

10 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(6-methoxy-pyridin-3-yl)-amine;

{2,3-Difluoro-6-[5-(2-pyridin-4-yl-pyrrolidin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;

or a pharmaceutically acceptable salt form thereof.

15 15. A compound of Claim 1 selected from the group of:

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-methanesulfonyl-ethyl)-methyl-amine;

N²-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N¹,N¹-dimethyl-1-phenyl-ethane-1,2-diamine;

20 {2,3-Difluoro-6-[5-(4-pyridin-2-ylmethyl-piperazin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-morpholin-4-yl-1-phenyl-ethyl)-amine;

25 {2,3-Difluoro-6-[5-(3-pyridin-4-yl-pyrrolidin-1-yl)-1,3,4-oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-methyl-(2-pyridin-4-yl-ethyl)-amine;

{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-methyl-(2-pyridin-2-yl-ethyl)-amine;

30 {5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-(2-morpholin-4-yl-2-pyridin-3-yl-ethyl)-amine;

N¹-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-1,3,4-oxadiazol-2-yl}-N²,N²-dimethyl-1-phenyl-ethane-1,2-diamine;

- 5

10

15

20

25

[6-(5-Ethyl-[1,3,4]oxadiazol-2-yl)-2,3-difluoro-phenyl]-(2-fluoro-4-iodo-phenyl)-amine;

[6-(5-Ethyl-[1,3,4]oxadiazol-2-yl)-2,3-difluoro-phenyl]-(4-ethynyl-2-fluoro-phenyl)-amine;

5 {6-[5-(3-Bromo-propyl)-[1,3,4]oxadiazol-2-yl]-2,3-difluoro-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;

{2,3-Difluoro-6-[5-(3-morpholin-4-yl-propyl)-[1,3,4]oxadiazol-2-yl]-phenyl}-(4-ethyl-2-fluoro-phenyl)-amine;

10 3-(4-{2,3-Difluoro-6-[5-(2-morpholin-4-yl-ethylamino)-[1,3,4]oxadiazol-2-yl]-phenylamino}-3-fluoro-phenyl)-propan-1-ol;

{5-[2-(4-Ethynyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-yl}-(2-morpholin-4-yl-ethyl)-amine;

1-(4-{2,3-Difluoro-6-[5-(2-morpholin-4-yl-ethylamino)-[1,3,4]oxadiazol-2-yl]-phenylamino}-3-fluoro-phenyl)-ethanone;

15 3-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2 (R)-diol;

3-{5-[2-(4-Ethynyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(R)-diol;

20 3-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(R)-diol;

3-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2 (S)-diol;

2-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,3-diol

25 2-{5-[2-(4-Ethynyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,3-diol;

{5-[3,4-Difluoro-2-(2-fluoro-4-vinyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-yl}-(2-morpholin-4-yl-ethyl)-amine;

30 2-(4-{2,3-difluoro-6-[5-(2-morpholin-4-yl-ethylamino)-[1,3,4]oxadiazol-2-yl]-phenylamino}-3-fluoro-phenyl)-ethanol;

2-{5-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylsulfanyl}-ethanol;

[6-(5-Allylsulfanyl-[1,3,4]oxadiazol-2-yl)-2,3-difluoro-phenyl]-(2-fluoro-4-iodo-phenyl)-amine;

2-{5-[3,4-Difluoro-2-(2-fluoro-4-methylsulfanyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,3-diol;

5 2-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,3-diol;

3-{5-[3,4-Difluoro-2-(2-fluoro-4-methylsulfanyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(R)-diol;

10 3-{5-[3,4-Difluoro-2-(2-fluoro-4-methylsulfanyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(S)-diol;

3-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(S)-diol;

3-{5-[2-(4-Ethynyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-propane-1,2(S)-diol;

15 2-{5-[3,4-Difluoro-2-(2-fluoro-4-methylsulfanyl-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino}-ethanol;

2-(4-{2,3-difluoro-6-[5-(2-methylamino-ethylamino)-1[1,3,4]oxadiazol-2-yl]-phenylamino}-3-fluoro-phenyl)-ethanol; or

20 N-(2-{5-[2-(4-Ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-ethyl)-N-methyl-acetamide;

Acetic acid 2-{5-[2-(4-ethyl-2-fluoro-phenylamino)-3,4-difluoro-phenyl]-[1,3,4]oxadiazol-2-ylamino}-ethyl ester

or a pharmaceutically acceptable salt form thereof.

25 18. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt or ester form thereof, and a pharmaceutically acceptable carrier.

30 19. A method of treating a proliferative disease in a patient in need thereof comprising administering a therapeutically effective amount of a compound of Claim 1.

20. A method for treating cancer in a patient in need thereof comprising administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

5 21. A method of Claim 19 wherein the cancer is brain, breast, lung, ovarian, pancreatic, prostate, renal, or colorectal cancer.

22. A method of treating neuropathic pain in a patient in need thereof comprising administering a therapeutically effective amount of a
10 compound of Claim 1.

23. A method of treating chronic pain in a patient in need thereof comprising administering a therapeutically effective amount of a compound of Claim 1.

15